Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Shares Outstanding (Diluted Average): 2010-2025

Historic Shares Outstanding (Diluted Average) for OptimizeRx (OPRX) over the last 15 years, with Q3 2025 value amounting to $19.5 million.

  • OptimizeRx's Shares Outstanding (Diluted Average) rose 620.15% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year increase of 620.15%. This contributed to the annual value of $18.3 million for FY2024, which is 682.13% up from last year.
  • Per OptimizeRx's latest filing, its Shares Outstanding (Diluted Average) stood at $19.5 million for Q3 2025, which was up 620.15% from $19.0 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Shares Outstanding (Diluted Average) ranged from a high of $19.5 million in Q3 2025 and a low of $16.1 million during Q1 2021
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $18.1 million (2021), whereas its average is $17.9 million.
  • In the last 5 years, OptimizeRx's Shares Outstanding (Diluted Average) surged by 2343.72% in 2021 and then crashed by 603.97% in 2023.
  • OptimizeRx's Shares Outstanding (Diluted Average) (Quarter) stood at $17.7 million in 2021, then rose by 0.53% to $17.8 million in 2022, then dropped by 3.71% to $17.1 million in 2023, then rose by 6.82% to $18.3 million in 2024, then increased by 6.38% to $19.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $19.5 million for Q3 2025, versus $19.0 million for Q2 2025 and $18.5 million for Q1 2025.